scholarly journals Transcriptome sequencing and metabolome analysis reveal the mechanism of Shuanghua Baihe Tablet in the treatment of oral mucositis

2021 ◽  
Vol 19 (12) ◽  
pp. 930-943
Author(s):  
Qi-Shun GENG ◽  
Rui-Juan LIU ◽  
Zhi-Bo SHEN ◽  
Qian WEI ◽  
Yuan-Yuan ZHENG ◽  
...  
Keyword(s):  
Oral Mucositis ◽  
Transcriptome Sequencing ◽  
Metabolome Analysis

scholarly journals Transcriptome Sequencing and Metabolome Analysis Reveal the Mechanism of Shuanghua Baihe Tablet in Treatment of Oral Mucositis

2021 ◽  
Author(s):  
Qishun Geng ◽  
Ruijuan Liu ◽  
Zhibo Shen ◽  
Qian Wei ◽  
Yuanyuan Zheng ◽  
...  
Keyword(s):  
Oral Mucositis ◽  
Acid Metabolism ◽  
Life Quality ◽  
Treg Cells ◽  
The Body ◽  
Interleukin 17 ◽  
Metabolome Analysis ◽  
Inflammatory Infiltration ◽  
Immune Balance ◽  
Tnf Α

Abstract Background: Oral mucositis (OM) caused by chemotherapy is the most common complication in the radiotherapy of head and neck tumors. In severe cases, it can lead to the interruption of treatment, which can affect the control of the disease and the life quality of patients. Shuanghua Baihe tablet (SBT) is a traditional Chinese medicine (TCM) formula, which is administerd to treat OM in China. It has been clinically effective for more than 30 years, but its mechanism is still unclear. With the rise of multiple omics, it is possible to study the mechanism of Chinese herbal compound prescriptions. Methods: Based on transcriptomics and metabolomics, we explored the mechanism of SBT in the treatment of OM. The OM model of rats was established by 5-FU induction, and SBT was orally administered at dosages of 0.75 and 3g/kg/day. In order to search for SBT targets and related metabolites, the dysregulated genes and metabolites were detected by transcriptomics and metabolomics. Immune related indicators such as interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) were detected by ELISA. Treg cell disorders was analyzed by flow cytometry. Results: Our results showed that SBT significantly alleviated the symptoms of OM rats and the inflammatory infiltration of ulcer tissues. After SBT administration, inflammatory related metabolic pathways including linoleic acid metabolism, valine, leucine and isoleucine biosynthesis were significantly altered. Furthermore, the production of proinflammatory factors like IL-17 and TNF-α, was also dramatically reduced after SBT administration. Besides, the infiltration degree of Treg cells in the spleen of OM model rats was significantly improved by SBT administration, thus maintaining the immune balance of the body.Conclusions: This study shows that SBT regulates inoleic acid metabolism, Glycerophospholipid metabolism and amino acid metabolism, and inhibits IL-17/TNF signal transduction to restore Treg and Th17 cell homeostasis in OM rats, thereby alleviating chemotherapy-induced OM.

Efficacy of keratinocyte growth factor in prevention of oral mucositis in children undergoing allogeneic hematopoietic cell transplantation

2020 ◽  
Vol 51 (3) ◽  
pp. 172-178
Author(s):  
Natalia Bartoszewicz ◽  
Krzysztof Czyżewski ◽  
Robert Dębski ◽  
Anna Krenska ◽  
Ewa Demidowicz ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cell Transplantation ◽  
Oral Mucositis ◽  
Hematopoietic Cell Transplantation ◽  
Clinical Course ◽  
Keratinocyte Growth Factor ◽  
Supportive Therapy ◽  
Primary Objective ◽  
Hematopoietic Cell ◽  
Unrelated Donor

AbstractIntroductionOral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.ObjectivesThe primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.Patients and methodsA total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.ResultsPatients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, p < 0.001), lower mucositis grade (median: 2° vs. 3°; p < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; p = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; p < 0.001).ConclusionsThe use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.

Sign in / Sign up

Export Citation Format

Share Document